The FDA staff on Monday said Biogen’s investigational ALS drug tofersen may have a “clinical benefit” on a rare and aggressive form of the disease.
You are here: Home / FDA staff says Biogen’s ALS drug may have a ‘clinical benefit’ on a rare form of the disease